Severe Protein-Losing Enteropathy Due to an Indolent Splenic Lymphoma: Case Report and Review of the Literature

Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):e165-e168. doi: 10.1016/j.clml.2018.12.015. Epub 2019 Jan 3.

Authors

Leonard Naymagon¹, Stephen Ward², Steven Naymagon³, Shyamala Navada⁴

Affiliations

¹ Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: leonard.naymagon@mountsinai.org.
² Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
³ Department of Medicine, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY.
⁴ Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.

PMID: 30685184
DOI: 10.1016/j.clml.2018.12.015

No abstract available

Keywords: Immunoglobulin deposition; Lymphangiectasia; Monoclonal protein; Rituximab; Splenic marginal zone lymphoma.

Publication types

Case Reports
Review

MeSH terms

Aged
Antineoplastic Agents, Immunological / administration & dosage
Female
Humans
Intestinal Mucosa / diagnostic imaging
Intestinal Mucosa / pathology
Intestinal Mucosa / physiopathology
Lymphoma, B-Cell, Marginal Zone / complications*
Lymphoma, B-Cell, Marginal Zone / drug therapy
Lymphoma, B-Cell, Marginal Zone / pathology
Lymphoma, B-Cell, Marginal Zone / physiopathology
Protein-Losing Enteropathies / drug therapy
Protein-Losing Enteropathies / etiology*
Protein-Losing Enteropathies / pathology
Protein-Losing Enteropathies / physiopathology
Rituximab / administration & dosage
Splenic Neoplasms / complications*
Splenic Neoplasms / drug therapy
Splenic Neoplasms / pathology
Splenic Neoplasms / physiopathology
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Rituximab